valsartan placebo

DRUG3 trials

Sponsors

Takeda, Duke University, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

Essential HypertensionHeart FailureMild-to-moderate Essential Hypertension

Phase 3

Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

CompletedNCT02480764

TakedaEssential Hypertension

Start: 2015-08-27End: 2017-10-13Updated: 2019-03-05

A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients

Not yet recruitingNCT06771245

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Mild-to-moderate Essential Hypertension

Start: 2025-01-24End: 2026-10-30Target: 606Updated: 2025-01-13

Phase 4

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

CompletedNCT02816736

Duke UniversityHeart Failure

Start: 2017-03-02End: 2020-09-29Updated: 2021-12-03

Related Papers

Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure: Analysis of the LIFE Trial Run-In.

2022-07-0117 citations

Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction

JAMA Cardiology2021-11-03163 citations

A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension

Medicine2020-08-048 citations

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.

2020-06-1036 citations